Taiwan Dr Yuan-Hung Hsu, President of MegaPro Biomedical, discusses the Taiwanese company’s evolution into a late-stage nanomedicine company, with two platforms targeting precision medicine. He highlights MPB 1523, a heavy-metal-free MRI contrast agent for liver cancer, and MPT 1734, a nanomicelle-based therapy for prostate cancer, while outlining MegaPro’s partnership strategy, cell-tracking…
Taiwan Jassy Wang, CEO of MegaPro Biomedical, a nanomedicine development company specializing in developing nanoparticles and nanomicelles, discusses the evolving nanomedicine market in Taiwan and reveals the company’s plans for future growth. Can you introduce MegaPro Biomedical to our readers? “Nanosize features many advantages; amongst them I would highlight the ability…
See our Cookie Privacy Policy Here
